Page 13 - Michael Erman News Today

(Reuters) -U.S. intelligence officials in late February told senators working on a biotech security bill that Chinese pharmaceutical firm WuXi AppTec had transferred U.S. intellectual property to Beijing without consent, according to two sources. The U.S. government is concerned that certain Chinese biotech companies are contributing technology or research and development for use by China's military, and the proposed legislation would restrict U.S. government funds going to those Chinese c...

A WuXi AppTec spokesperson said: "We are not aware of any unauthorized transfers by WuXi AppTec of any U.S. clients data or intellectual property to China. Safeguarding our customers information is of the utmost importance to us, and we store it in keeping with their direction."

The U.S. Food and Drug Administration on Tuesday approved Merck's treatment for adults with high blood pressure due to constriction of lung arteries, adding another...

The U.S. FDA on Tuesday approved Mercks treatment for adults with high blood pressure due to constriction of lung arteries, adding another potential blockbuster drug to the pharmaceutical giants...

(This March 26 story has been corrected to remove reference to follicle-stimulating hormone, in paragraph 8) By Leroy Leo and Michael Erman (Reuters) - ...

(Reuters) - The U.S. Centers for Disease Control and Prevention (CDC) director on Wednesday signed off on the use of updated COVID vaccines as a second annual shot for adults aged 65 and older. The final recommendation from director Mandy Cohen com...

Pfizer on Thursday said a single dose of its new respiratory syncytial virus (RSV) vaccine Abrysvo maintained its ability to protect against the illness through a second year of respiratory disease season. The company said in a press release that the vaccine's efficacy against RSV-associated lower respiratory tract disease with three or more symptoms was 77.8% through season two, compared with efficacy of 88.9% after the first RSV season, which led to the shot's U.S. approval. Cumula...

The final recommendation from director Mandy Cohen comes after an expert advisory group to the CDC on Wednesday said U.S. adults aged 65 and older should get a second annual COVID-19 shot this spring, strengthening their recommendations from last year. The CDC's Advisory Committee For Immunization Practices (ACIP) voted 11-1 to say that older Americans should get another shot this spring, according to the agency.

An expert advisory group to the U.S. Centers for Disease Control and Prevention on Wednesday said U.S. adults aged 65 and older should get a second annual COVID-19 shot this spring, strengthening... -February 28, 2024 at 04:36 pm EST - MarketScreener

The final recommendation from director Mandy Cohen comes after an expert advisory group to the CDC on Wednesday said U.S. adults aged 65 and older should get a second annual COVID-19 shot this spring, strengthening their recommendations from last year. The CDC's Advisory Committee For Immunization Practices (ACIP) voted 11-1 to say that older Americans should get another shot this spring, according to the agency.